Abstract

Cancer is known as a group of cells that divide without control and divided into two types, malignant tumor which spread to other parts of the body and benign tumor which not spread and is treated by surgery for example to remove the tumor. Breast cancer is the second cause of death and life-threatening among women worldwide so many kinds of research had been performed to understand and treat breast cancer so many treatments had been discovered to treat breast cancer. Pomegranate and its constituents have been shown to affect cell signaling and pathways involved in inflammation, proliferation, tumorigenesis, and angiogenesis in multiple in vitro studies. Several studies demonstrated that pomegranate extract and juice has anticancer activity in breast cancer cell lines. In this study, MTT assay, cell cycle analysis and real-time PCR were performed to test the anticancer effect of pomegranate phenolic compounds extracted from seeds on GADD45A gene expression in (MDA) breast cancer cells and occurred upregulation to GADD45A tumor suppressor gene and the cell viability is decreased.

Keywords: GADD45A; Breast Cancer; Tumor Suppressor

References

1. Siegel RL., et al. “Cancer statistics”. A Cancer Journal for Clinicians 68.1 (2018): 7-30. 
2. Desantis CE., et al. “Cancer treatment and survivorship statistics”. A Cancer Journal for Clinicians 64.4 (2014): 252-271. 
3. Vidua-Martos M., et al. “Pomegranate and it is many functional components as related to human health: a review”. Comprehensive Reviews in Food Science and Food safety 9.6 (2010): 635-645.
4. Hanahan D and RA Weinberg. “Hallmarks of cancer: the next generation”. Cell 144.5 (2011): 646-674.
5. Langie SAS., et al. “Causes of genome instability: the effect of low dose chemical exposures in modern society”. Carcinogenesis 36.1 (2015): 61-88.
6. Lee EYHP and WJ Muller. “Oncogenes and tumor suppressor genes”. Cold Spring Harbor Perspective in Biology 10.11 (2018): a003236.
7. Hassanpour SH and MA Dehghani. “The cancer from perspective of molecular”. Journal of Cancer Research and Practice 4.4 (2017): 127-129.
8. Siegel RL., et al. “Cancer statistics”. A Cancer Journal for Clinicians 66.1 (2016): 7-30. 
9. Schottenfeld D and JF Fraumeni. “Cancer epidemiology and prevention”. New York: Oxford University Press 8.1 (2006): 16-27.
10. Plimmer M., et al. “Global burden of cancers attributable to infections: a synthetic analysis”. The Lancet Global Health 4.9 (2016): 609-616.
11. Golemis EA., et al. “Molecular mechanisms of the preventable causes of cancer in the United States”. Genes and Development 32 (2018): 868-902.
12. Antwi SO., et al. “Exposure to environmental chemicals and heavy metals, and risk of pancreatic cancer”. Cancer Causes Control 26.11 (2015): 1583-1591. 
13. Shaper AG., et al. “Pipe and cigar smoking and major cardiovascular events, cancer incidence and all-cause mortality in middle-aged British men”. International Journal of Epidemiology 32.5 (2003): 802-808.
14. Linehan WM., et al. “Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics”. Clinical Cancer Research 13.2 (2007): 671s-679s. 
15. Velez AMA and MS Howard. “Tumor-suppressor genes, cell Cycle regulatory checkpoints, and the skin”. North American Journal of Medical Sciences 7.5 (2015): 176-188.
16. Ford D., et al. “Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium”. American Journal of Human Genetics 62.3 (1998): 676-689.
17. Steelman LS., et al. “Combining chemotherapy, hormonal therapy and targeted therapies to treat breast cancer”. Molecular Medicine Reports 1 (2008): 139-160.
18. Roy R., et al. “BRCA1 and BRCA2: different roles in a common pathway of genome protection”. Nature Reviews Cancer 12.1 (2012): 68-78.
19. Lee DS., et al. “Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients”. Breast Cancer Research 14.2 (2012): 1.
20. Haiman CA., et al. “Common genetic variation at PTEN and risk of sporadic breast and prostate cancer”. Cancer Epidemiology Biomarkers Prevention 15.5 (2006): 1021-1024.
21. McCubery JA., et al. “Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance”. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1773.8 (2007): 1263-1284.
22. Nakamura M., et al. “Calcitonin targets extracellular signal-regulated kinase signaling pathway in human cancers”. Journal of Molecular Endocrinology 39.6 (2007): 375-384.
23. Eroles P., et al. “Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways”. Cancer Treatment Reviews 38.6 (2012): 698-707.
24. Faria A and C Calhau. “The bioactivity of pomegranate: impact on health and disease”. Critical Reviews in Food Science and Nutrition 51.7 (2011): 626-634.
25. Elfalleh W., et al. “Total phenolic contents and antioxidant activities of pomegranate peel, seed, leaf and flower”. Journal of Medicinal Plants Research 6.32 (2012): 4724-4730.
26. Sturgeon SR and AG Ronnenberg. “Pomegranate and breast cancer: possible mechanisms of prevention”. Nutrition Reviews 68.2 (2010): 122-128.
27. Kim ND., et al. “Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer”. Breast Cancer Research and Treatment 71.3 (2002): 203-217.
28. Adams LS., et al. “Pomegranate juice, total pomegranate ellagitannins, and punicalagin suppress inflammatory cell signaling in colon cancer cells”. Journal of Agricultural and Food Chemistry 54 (2006): 980-985.
29. Sreekumar S., et al. “Pomegranate extract demonstrate a selective estrogen receptor modulator profile in human tumor cell lines and in vivo models of estrogen deprivation”. The Journal of Nutritional Biochemistry 23.7 (2011): 725-732.
30. Shirode AB., et al. “Antiproliferative effects of pomegranate extract in MCF-7 breast cancer cells are associated with reduced DNA repair gene expression and induction of double strand breaks”. Molecular Carcinogenesis 53.6 (2014): 458-470.
31. D'Amours D and SP Jackson. “The MRE11 complex: at the crossroads of DNA repair and checkpoint signalling”. Nature Reviews Molecular Cell Biology 3.5 (2002): 317-327.
32. Kasimsetty SG., et al. “Colon cancer chemopreventive activities of pomegranate ellagitannins and urolithins”. Journal of Agricultural and Food Chemistry 58.4 (2010): 2180-2187.
33. Helleday T., et al. “DNA double-strand break repair: from mechanistic understanding to cancer treatment”. DNA Repair 6.7 (2007): 923-935.
34. Kass EM and M Jasin. “Collaboration and competition between DNA double‐strand break repair pathways”. FEBS Letters 584.2 (2010): 3703-3708.
35. Dikmen M., et al. “The antioxidant potency of Punica granatum L. fruit peel reduces cell proliferation and induces apoptosis on breast cancer”. Journal of Medicinal Food 14.12 (2011): 1638-1646.
36. Sakamoto T., et al. “Effects of diverse dietary phytoestrogens on cell growth, cell cycle and apoptosis in estrogen-receptor-positive breast cancer cells”. Journal of Nutritional Biochemistry 21.9 (2010): 856-864.
37. Hastak K., et al. “Ablation of either p21 or Bax prevents p53-dependent apoptosis induced by green tea polyphenol epigallocatechin-3-gallate”. The FASEB Journal 19.7 (2005): 789-791.
38. Aizawa K., et al. “Tobacco carcinogen induces both lung cancer and non‐alcoholic steatohepatitis and hepatocellular carcinomas in ferrets which can be attenuated by lycopene supplementation”. International Journal of Cancer 139.5 (2016): 1171-1181.
39. Bates S., et al. “Cell cycle arrest and DNA endoreduplication following p21Waf1/Cip1 expression”. Oncogene 17 (1998): 1691-703.
40. Sreeja S., et al. “Pomegranate extract demonstrate a selective estrogen receptor modulator profile in human tumor cell lines and in vivo models of estrogen deprivation”. The Journal of Nutritional Biochemistry 23.7 (2012): 725-732.

Citation

Citation: Mahmoud Mohamed Helmy. "In Vitro Study of Pomegranate Seed Extract on GADD45A Gene Expression in (MDA) Breast Cancer Cells".Acta Scientific Pharmacology 1.4 (2020).

Copyright

Copyright: © 2020 Mahmoud Mohamed Helmy. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.